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Background: An increasing number of researchers are focused on strategies for developing inhibitors of
Mycobacterium tuberculosis (Mtb) as tuberculosis (TB) drugs.
Results: In order to learn from prior work we have collated information on molecules screened versus Mtb and
their targets which has been made available in the Collaborative Drug Discovery (CDD) database. This dataset
contains published data on target, essentiality, links to PubMed, TBDB, TBCyc (which provides a pathway-based
visualization of the entire cellular biochemical network) and human homolog information. The development of
mobile cheminformatics apps could lower the barrier to drug discovery and promote collaboration. Therefore we
have used this set of over 700 molecules screened versus Mtb and their targets to create a free mobile app
(TB Mobile) that displays molecule structures and links to the bioinformatics data. By input of a molecular structures
and performing a similarity search within the app we can infer potential targets or search by targets to retrieve
compounds known to be active.
Conclusions: TB Mobile may assist researchers as part of their workflow in identifying potential targets for hits
generated from phenotypic screening and in prioritizing them for further follow-up. The app is designed to lower
the barriers to accessing this information, so that all researchers with an interest in combatting this deadly disease
can use it freely to the benefit of their own efforts.
Keywords: Collaborative drug discovery tuberculosis database, Drug discovery, Mobile applications, Mycobacterium
tuberculosis, Tuberculosis, TB MobileBackground
Modern drug discovery must be more time- and cost-
efficient in discovering novel therapeutics. These chal-
lenges are felt even more significantly in the search for
neglected disease treatments. A prime example is tuber-
culosis (TB), caused by Mycobacterium tuberculosis (Mtb),
which infects approximately one-third of the world’s popu-
lation and results in 1.7–1.8 million deaths annually [1].
New drugs active against Mtb are urgently needed to com-
bat a pandemic heavily affected by resistance to available
therapies and co-infection with HIV/AIDS [2]. The pipe-
line for TB therapeutics had not produced a new approved
drug in over 40 years [3,4]. Only a tiny fraction of TB* Correspondence: ekinssean@yahoo.com
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reproduction in any medium, provided the ortargets have been addressed with approved drugs and re-
cent testing has targeted additional proteins but this has
yet to result in a drug besides bedaquiline for multidrug
resistant TB [5,6]. This is a pattern observed for other anti-
bacterial targets reflecting the difficulty of target-based
high-throughput screening [7]. In recent years there has
been an increase in the efforts around high throughput
screening (HTS) for Mtb, in order to find compounds as
therapeutics against TB [8-12] at a cost of millions of dol-
lars, with resultant low single-digit (or less) hit rates
[8,9,13,14]. Whole cell screening, however does not provide
any information on the targets for the hits that result and
this therefore entails costly follow up. In many cases such
target identification is unable to identify one or more target.
While there have been studies that evaluate the role of
particular Mtb genes and define their potential as targets
for new drugs [15] there have been few efforts to predict
targets for hits coming from whole cell screening. Vari-
ous TB-related databases [16] are available that coverl Ltd. This is an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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phylogenetic trees, active compounds, large-scale screening
data, resistance-associated mutations, targets, comparative
analysis and gene expression data. Pipelines for bio-
informatics processes such as target identification in TB
(e.g. targetTB [17]) have also been suggested. We created
a collection of >700 molecules with Mtb target/s along
with published data on the target, essentiality, links to
literature (PubMed), genes (tbdb.org), pathways (TBCyc,
which provides a pathway-based visualization of the entire
cellular biochemical network) and human homolog infor-
mation [18] collated in the course of a previous study [19].
This dataset was made available in the Collaborative Drug
Discovery (CDD) database [18].
As mobile devices such as smartphones and tablet com-
puters have seen rapid uptake in recent years and the asso-
ciated app stores include a growing number of chemistry
software apps [20], making data available as an app may
help reach a wider audience. These mobile apps generally
perform one or two functions and can be thought of as
individually packaged features rather than the relatively
heavyweight programs commonly used in desktop com-
puting. However, such apps can use data interchange and
be used in the workflow to increase the productivity of
chemists [21,22]. Mobile apps for chemistry are a nascent
area to delivering or "appifying" data and may be disruptive
to many currently used paradigms for presenting informa-
tion and for education [23]. A recent example is the Green
Solvents mobile App which took data collected on solvents
and delivered it as a free look-up tool to help in solvent
selection [24].
The recent collation of molecules screened versus Mtb
and their targets could help in the task of suggesting
potential targets for HTS hits [19]. This data was used
to create the TB Mobile app that displays molecule
structures and links to the bioinformatics data. By input
of a molecule structure and performing a similarity
search one can infer potential targets or search by targets
to retrieve compounds known to be active. The app also
has filters to limit the visible molecules by target name,
pathway name, essentiality and human ortholog. We now
describe TB Mobile [25,26] and its potential applications.
Methods
Dataset curation
The process of dataset curation can be broken down
into several steps.
1. Identification of essential in vivo enzymes of Mtb
involved intensive literature mining and manual
curation, to extract all the genes essential for Mtb
growth in vivo across species [27-31].
2. Homolog information was collated from other
studies [28,32].3. Collection of metabolic pathway information
involved using TB database (TBDB) [33,34].
4. Identifying molecules and drugs with known or
predicted targets [35] involved searching the CDD
databases for manually curated data. The structures
and data were exported for combination with the
other data.
5. All data were combined with URL links to literature
and TBDB [33,34] and deposited in the CDD
database [18].
TB Mobile app software development
The iOS app was build using the Objective-C program-
ming language, with the API provided by Apple for na-
tive iOS development, while the Android app was built
using Java and the standard Android API. The apps have
almost identical functionality, with minor aesthetic differ-
ences due to the platform. Both of these apps are linked
with MMDSLib, which is available separately for both
platforms, and provides the core functionality for a num-
ber of cheminformatics apps, such as the Mobile Molecu-
lar DataSheet (MMDS) [36].
The TB related information was entered manually, and
is bundled as part of the app resources. The TB Mobile
app was developed as described above then made avail-
able on iTunes [25] as a free app for the iPhone, iPod
and iPad platforms. The Android version is available free
of charge on Google Play [26].
TB Mobile app software application
The TB Mobile app uses molecule structures grouped as
the primary point of entry. These molecules are listed with
the targets. The user can use the swiping gesture to scroll
through all the solvents, then tap on a molecule of inter-
est. This opens a box which lists the molecule name, CDD
number, and resistance information. A second box lists
the target (Rv number), a link to TBDB, homolog informa-
tion, essentiality information, pathway information and
gene links to PubMed. Links out to open in other mobile
apps like ChemSpider [37], the Mobile Reagents app [38]
and MMDS etc. [39] are also provided.
Similarity searching in TB Mobile app
Similarity comparisons are done by computing simple
typed graph fingerprints (up to 4 atoms in size) and com-
puting the Tanimoto coefficient, which gives an indication
of structural similarity. Most similar compounds are listed
first (from top left to bottom right) in the app.
Predictions targets for new compounds
Molecules active against Mtb were identified in recent
publications from different groups, these included HTS.
Proposed targets for some of these molecules were also
identified in these publications, in some cases. These
Figure 1 Appearance of the TB Mobile app and identification
of functions on an iPhone. The appearance of TB Mobile on an
Android Tablet.
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use of the app. First they were all drawn in the MMDS
app and copied into the TB Mobile app (an example of
app-to-app communication). Molecules can also be drawn
within the TB Mobile app itself. The similarity searching
component was used to rank the content in TB Mobile of
molecules with known targets. We have used this as an
example of inferring potential targets and compared this
to the published data for these molecules. It should be
noted that such data is far from definitive as these pub-
lished compounds have not been tested versus all Mtb
targets and it is possible the same compound may be
active against more than one target.
Results
Dataset curation
Over 700 molecules with target related information from
the literature were curated for use in CDD and TB Mobile.Figure 2 A. Molecule detail and links on the TB Mobile app on an iPh
Android Tablet.TB Mobile
When the app first opens, it takes a moment to organize
its data, then displays the main screen (Figure 1). The
screen is divided into two blocks: the control block on
top, and the compound list underneath. The control
block provides means for searching, sorting and filtering
the compound list, as well as access to menus, which
will be discussed below. The compound list is a vertically
scrollable list of compounds, which are indicated pri-
marily by structure, and annotated by name (if available)
and target codes. Tapping on any of the compound but-
tons brings up the corresponding detail view (Figure 2).
Most of the detail view is composed of a scrollable
list, which shows all of the available information about
the compound. In the above example, the structure of
isoniazid is shown at the top, along with its name, CDD
number, and resistance information. Each of the known
target interactions is summarized, which in this case in-
cludes InhA. For each target, a variety of information is
shown, including human homolog information, whether
the target interaction is essential for activity, known bio-
chemical pathways, and a number of links to available
reference information. The links can be clicked on, and
will launch the mobile browser, providing a significant
amount of further detail. The top of the detail view con-
tains several button icons (Figure 3). The select button
toggles the bookmark state for the compound. Book-
marked compounds are annotated on the main screen
by a folded top right corner (Figure 4). The ‘copy’ button
places a copy of the structure onto the device clipboard,
so it can be pasted into other mobile apps, or pasted
into the molecular structure search box (described in
the next section). The open-in button presents a list of
installed apps that are capable of opening molecular
structures. If one is selected, then that app is launched
and provided with the current structure. The control
block provides several ways to modify which compounds
are listed, and in what order. Note that if none of theseone. B. Molecule detail and links on the TB Mobile app on an
Figure 3 App details in the TB Mobile app on an iPhone.
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displayed, and their order is selected randomly. To
restrict the list of compounds to those whose names
contain a certain search string, or CDD number, enter
text in the search box (Figure 5). Now only clotrimazole
and econazole are shown. Many of the compounds cur-
rently have no common name, and so will be excluded
from this search.
Structural similarity sorting is accomplished by tap-
ping on the structure box at the top right, which allows
a chemical structure to be either pasted from the clip-
board, or drawn directly using the built in sketcher. The
structure sketcher is based on the powerful gesture-Figure 4 Searching for a molecule in the TB Mobile app on
an iPhone.based drawing tools originally developed for the MMDS
app, which are designed to make touch-based structure
editing fast and effective [40]. For casual users, the app
also provides an option to use a less powerful version
of the sketcher which is more familiar to users of con-
ventional desktop tools, and so has almost no learning
curve. Once the structure is provided, either by editing
or pasting, the compound list is sorted according to
fingerprint-based similarity to the reference structure
(Figure 6). The TB Mobile app can also be opened from
other apps that can launch structures (e.g. MolPrime
[41]). In this case, the app will perform the structure
similarity ordering immediately upon launch.
The control block shows several buttons for filtering
(Figure 7). The essential and homolog filters behave simi-
larly: tapping either of these buttons brings up a selec-
tion menu with three options (Figure 8). The default
state is ‘Maybe’, i.e. no filtering. Selecting ‘Yes’ limits the
compound list to only those which have at least one tar-
get which is considered essential for activity, or has a
human homolog, respectively. Selecting ‘No’ limits the
compound list to those which do not have a target satis-
fying the constraint. The gene filter button brings up a
dialog that presents a list of target genes (Figure 9). EachFigure 5 Searching by name in the TB Mobile app on
an iPhone.
Figure 6 TB Mobile can be used to rank molecules according to their similarity to a reference structure, which can infer potential
targets. A. an example in iOS version B. an example in the Android version.
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will be restricted to those which have activity information
about at least one of the selected genes. Similarly, path-
ways filter button allows known pathways to be selected
from an inclusive list (Figure 10). The action menu is acti-
vated by pressing the cog icon at the top left (Figure 11).
The ‘Open in’ and ‘Send by Email’ actions refer to the
compounds that are currently displayed onscreen: these
can be bundled into a datasheet and handed off to an app
that is capable of handling them (e.g. MMDS, SAR Table
[42]), or composed as an outgoing email. Outgoing emails
include the compounds as an MDL SDfile attachment.
These two techniques make it possible to select a subset
of the content in TB Mobile and use it with other apps, or
make it available to collaborators. There are several menu
actions for handling the bookmarked state: bookmarking
all currently listed compounds, viewing only bookmarked
compounds, and clearing bookmarks.
Predicting targets for new compounds
In order to illustrate a workflow for using the mobile app
we have curated an additional set of 20 molecules pub-
lished since 2009 that have activity against Mtb and were
identified by HTS or other methods (Table 1). In someFigure 7 Data can also be filtered by target name, pathway name, es
app on an iPhone.cases purported targets are known and experimentally
verified, while in others a mechanism may be known but a
target or targets is unknown. For some, there is no known
target and the mechanism is unknown. In each case we
have used just the input 2D structure of the molecule in
TB Mobile to perform a similarity search of the dataset
in the app (Additional file 1: Figures S1-S20 illustrate just
the first screen of compounds returned in similarity order
to the query molecule). The target for the molecule that
is ranked most similar is listed for comparison. Some
interesting examples stand-out such as pyridomycin,
which was recently shown to target InhA (Rv1484) [43],
and TB Mobile was able to rank an InhA inhibitor second
(Additional file 1: Figure S12). Gliotoxin was found in a
recent HTS screen and resistant mutants could not be
generated, so the target was not described [9]. However,
this molecule was found to be in TB Mobile (Additional
file 1: Figure S13) annotated with the target mycothiol-S-
conjugate amidase (Mca, Rv1082) and had been discov-
ered previously [44]. In some cases there are very few
molecules which represent inhibitors of a particular tar-
get. For example there are only two molecules in TB
Mobile that target alanine racemase (Alr, Rv3423c) and
two that target dihydrofolate reductase (DfrA, Rv2763c).sentiality and human ortholog as shown here in the TB Mobile
Figure 8 Filtering by homolog in the TB Mobile app on
an iPhone.
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by HTS [45]. In TB Mobile, a molecule that targets S-
adenosylhomocysteine hydrolase (SahH, Rv3248c) is ranked
first while the known alr inhibitor, D-cycloserine is ranked
12th out of the set of over 700 compounds (Additional file 1:
Figure S1). NC000221 is proposed to target DfrA [46]. Que-
rying TB Mobile with this compound ranked ethambutol
as the most similar. Ethambutol targets EmbA (Rv3794),
EmbB (Rv3795) and EmbC (Rv3793) and is ranked first
while isoniazid (which has many targets including DfrA
[47]) was ranked 25th (Additional file 1: Figure S7). ThisFigure 10 Filtering by pathways in the TB Mobile app on
an iPhone.
Figure 11 Options for sharing data in the TB Mobile app on
an iPhone.Figure 9 Filtering by genes in the TB Mobile app on an iPhone.
Table 1 Molecules active against Mtb evaluated in TB Mobile app
Molecule Name Notes from literature TB Mobile results most similar Reference
L2-04 Proposed target is Alr SahH (D-cycloserine ranked 12th) [45]
L2-05 Proposed target is Alr SahH [45]
L2-06 Proposed target is Alr SahH [45]
L2-10 Proposed target is Alr DapA [45]
L2-12 Proposed target is Alr SahH [45]
L2-13 Proposed target is Alr ThiL [45]
NC00094221 Proposed target is DfrA EmbA, EmbB, EmbC
(Isoniazid ranked 25th (DfrA))
[46]
DNB1 DprE1/ DprE2 InhA [49]
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Table 1 Molecules active against Mtb evaluated in TB Mobile app (Continued)
Mirandamycin Proposed-quinol oxidase FolP1, FolP2 [50]
cpd 3 Glyoxylase (rv0577) FtsZ [51]
377790 DprE1 ThiL [9]
Pyridomycin InhA Def (InhA ranked 2nd) [43]
Gliotoxin Not described Mca (Molecule in database) [9]
A039 Glycerol dependent InhA [9]
C215 MmpL3 Cyp51, Cyp121,Cyp130 [9]
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Table 1 Molecules active against Mtb evaluated in TB Mobile app (Continued)
Oxyphenbutazone none InhA [48]
7759844 Mt-Guab2 InhA [52]
GNF-NITD 46 Inhibit ATP homeostasis Dxs1 [8]
GNF-NITD 82 Inhibit ATP homeostasis CysH [8]
GNF-NITD101 Inhibit ATP homeostasis SahH [8]
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zid that are known to be activated in order to have activity
[47]. In other cases there are no representatives of a
particular target in TB Mobile e.g. MmpL3 (Rv0206c) [9].
Recently the approved drug oxyphenbutazone (OPB) was
identified by HTS as having Mtb activity under aerobic and
a 4-stress model of nonreplication [48], although a specific
target was not identified. All activity of OPB was shown to
be dependent on the acid- and NO dependent conversion
of OPB to 4-OH-OPB, which was active on both replicating
and non-replicating Mtb. Searching in TB Mobile suggests
InhA as a potential target (Additional file 1: Figure S16).
Demonstrating that the app retrieves first line drugs
Fourteen first line drugs active against Mtb from a review
[53] were used to demonstrate that the molecules are re-
trieved first and that similar molecules are in the top posi-
tions (Table 2). In all cases the query compound is retrievedfirst. In many cases the second and third molecules are
closely related with identical targets (e.g. amikacin, kanamy-
cin and streptomycin). In others the molecules are structur-
ally similar but known targets are different e.g. ethionamide
(InhA), prothionamide (SahH) and nicotinamide (SahH).
This may be useful for suggesting potential additional tar-
gets of compounds for which it is still unclear. An example
here is pyrazinamide which is activated to pyrazinoic acid
which may have several targets [54,55] (Table 2).
Discussion
Within pharmaceutical companies, computational ap-
proaches are widely used to aid in drug discovery, but have
not been as extensively applied for TB research. We have
found several gaps when we look at how computational
methods could be used in TB drug discovery including
assessing drug-likeness or lead-likeness [56], target decon-
volution [35,57], use of sequential virtual and biochemical
Table 2 First line drugs active against Mtb evaluated in TB Mobile app and the top 3 molecules














Capreomycin 1A Capreomycin 1A (TlyA) Capreomycin 1B
(RplJ, TlyA)
Capreomycin (RplJ)
Capreomycin 1B Capreomycin 1B
(RplJ, TlyA)
Capreomycin (TlyA) Capreomycin (RplJ)






Ethionamide Ethionamide (InhA) Prothionamide (SahH) Nicotinamide (SahH)
Gatifloxacin Gatifloxacin (GyrA) Moxifloxacin (Murd, PurU) Ciprofloxacin (GyrA)
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Table 2 First line drugs active against Mtb evaluated in TB Mobile app and the top 3 molecules (Continued)
Isoniazid Isoniazid (InhA, KasA, DfrA) Nicotinamide (SahH) Ethionamide (InhA)
Kanamycin Kanamycin
























This illustrates they are in the app and that similar molecules with their targets are retrieved.
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ism, excretion and toxicity (ADME/Tox) predictions [16].
In the current study we address the target deconvolution
issue and methods to assist in prioritization of Mtb hits.
In developing mobile apps for cheminformatics we
have assumed that many scientists now have a smart-
phone and/or tablet computer, and that a large majority
of these are iOS- or Android-based. Our research aims
to deliver cheminformatics solutions via mobile apps as
they are easier to use when in the laboratory or in loca-
tions without a desktop computer. The TB Mobile app is
an example of a reference tool which stores its data lo-
cally on the device, so its primary functionality is avail-
able even when there is no network connection. While
e-lab notebooks are generally used in the office, in con-
trast a mobile phone will be in the scientists pocket at
all times and apps can be used anywhere, anytime and
are generally intuitive. Early mobile cheminformatics apps
concentrated on solving foundational technical problems
like providing a fully functional sketcher on a small, under-
powered touchscreen device, and making available compu-
tational services [20,21]. TB Mobile is representative of a
follow up category which builds on the technical success of
the core functionality to provide a very specific product
that is highly tuned to the needs of a small but high impact
demographic, namely scientists working toward cures for a
neglected disease.
We have illustrated a workflow in which compounds
derived from Mtb HTS or other screening could be
input into TB Mobile to perform a similarity search. This
enables the user to see if the compound had been previ-
ously identified by others (like gliotoxin, Table 1) and also
what the most similar molecules are and their known tar-
gets (Table 1, Table 2). This could help with potential
follow-up and experimental validation. Of course there
are examples of molecules that are active in vitro due to
the experimental conditions and when tested in in vivo
they have no activity [51], which is an experimental
artifact that TB Mobile cannot predict. For some mole-
cules there may be many potential targets in Mtb. Even if
a molecule has one published target that does not prevent
it from having another potential target, it just might not
have been experimentally verified. We are not suggesting
TB Mobile is a definitive target prediction tool, it certainly
is not as sophisticated as other methods that use Bayesian
[35] and other methods [57]. It does however set the
stage to consider what is possible with a scientific mobile
app. While molecular similarity may not be the most
accurate method to predict potential targets, it is fast and
interpretable. Future methods may use more predictive ma-
chine learning models [56,58] but will require expansion of
the training set of molecules with targets. We envisage in
future that updating the content of the app with molecules
and targets not currently represented e.g. adding moleculesthat target MmpL3 and others should enhance the utility of
TB Mobile as well as balance out the heavy bias towards
targets that are over represented and which occur more fre-
quently in the results (e.g. InhA). One could also consider
addition of some weighting or scoring that would normalize
the similarity search for the frequency of a target in the
dataset. To date there are representatives of 68 targets that
likely are the most important targets over the past decade.
We hope to add compounds that represent inhibitors of
newer targets in future updates.
Conclusion
In summary, TB Mobile is a simple to use app with use-
ful functionality for viewing and manipulating data about
compounds with activity against Mtb, their targets and
other related information. The app represents a significant
development in the effort to make accessible drug discovery
data freely available in a form that is highly useful to
scientists in general, not just cheminformatics experts. The
mobile app is freely available for iOS (iPhone, iPod, iPad)
and Android devices and will be updated regularly.
Additional file
Additional file 1: The results of the similarity searches for compounds
in Table 1 are shown in Additional file 1: Figures S1-S20. The TB
Mobile app is freely available from the Apple iTunes AppStore [25] and
Google Play [26].
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